These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 10914702)
21. BLCA-4 and UBC combined detection for early diagnosis of bladder cancer. Cui L; Sun MM; Zhao ZH; Yang JP; Zheng YP; He LL; Chen KS; Fan QX J Biol Regul Homeost Agents; 2016; 30(2):485-90. PubMed ID: 27358136 [TBL] [Abstract][Full Text] [Related]
22. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder. Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234 [TBL] [Abstract][Full Text] [Related]
23. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433 [TBL] [Abstract][Full Text] [Related]
24. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897 [TBL] [Abstract][Full Text] [Related]
25. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor. Casella R; Huber P; Blöchlinger A; Stoffel F; Dalquen P; Gasser TC; Lehmann K J Urol; 2000 Dec; 164(6):1926-8. PubMed ID: 11061883 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer. Chang YH; Wu CH; Lee YL; Huang PH; Kao YL; Shiau MY Urology; 2004 Oct; 64(4):687-92. PubMed ID: 15491702 [TBL] [Abstract][Full Text] [Related]
27. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Friedrich MG; Weisenberger DJ; Cheng JC; Chandrasoma S; Siegmund KD; Gonzalgo ML; Toma MI; Huland H; Yoo C; Tsai YC; Nichols PW; Bochner BH; Jones PA; Liang G Clin Cancer Res; 2004 Nov; 10(22):7457-65. PubMed ID: 15569975 [TBL] [Abstract][Full Text] [Related]
28. Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer. Tzai TS; Tsai YS; Shiau AL; Wu CL; Shieh GS; Tsai HT Urology; 2006 Feb; 67(2):294-9. PubMed ID: 16461079 [TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379 [TBL] [Abstract][Full Text] [Related]
31. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder. Jamshidian H; Kor K; Djalali M Urol J; 2008; 5(4):243-7. PubMed ID: 19101898 [TBL] [Abstract][Full Text] [Related]
32. Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment. Avgeris M; Mavridis K; Tokas T; Stravodimos K; Fragoulis EG; Scorilas A Carcinogenesis; 2015 May; 36(5):528-37. PubMed ID: 25804644 [TBL] [Abstract][Full Text] [Related]
33. The role of urinary cytology for detection of bladder cancer. Planz B; Jochims E; Deix T; Caspers HP; Jakse G; Boecking A Eur J Surg Oncol; 2005 Apr; 31(3):304-8. PubMed ID: 15780568 [TBL] [Abstract][Full Text] [Related]
34. [Screening methods in the detection of bladder cancer: comparison of nuclear matrix protein-22, bladder tumor antigen and cytological examinations]. Fukui Y; Samma S; Fujimoto K; Akiyama T; Yamaguchi A; Hirayama A Hinyokika Kiyo; 2001 May; 47(5):311-4. PubMed ID: 11433750 [TBL] [Abstract][Full Text] [Related]
35. Immunostaining of cytokeratin 20 in cells from voided urine for detection of bladder cancer. Golijanin D; Shapiro A; Pode D J Urol; 2000 Dec; 164(6):1922-5. PubMed ID: 11061882 [TBL] [Abstract][Full Text] [Related]
36. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma. Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551 [TBL] [Abstract][Full Text] [Related]
37. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder. Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567 [TBL] [Abstract][Full Text] [Related]
38. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628 [TBL] [Abstract][Full Text] [Related]
39. [Expression of cyclooxygenase-2 in human transitional cell bladder carcinomas]. Zhan J; Tang XD Ai Zheng; 2002 Nov; 21(11):1212-6. PubMed ID: 12526218 [TBL] [Abstract][Full Text] [Related]
40. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]